Drug intelligence / Profile preview

BR-9003

Development stage: Unknown
Lead developer: Boryung
Modality: Small Molecules
Administration: Oral

Overview

BR-9003 is a new molecular entity developed by Boryung Pharmaceutical for smoking cessation. The drug was investigated as an oral therapy to aid in smoking withdrawal, with clinical development conducted in South Korea. Its precise mechanism of action has not been defined or disclosed publicly. Development reached phase I clinical trials but was discontinued before progressing further[1][2][4].

Other names: varenicline SRvarenicline sustained release

Targets

α4β2 nAChR (Nicotinic acetylcholine receptor alpha4 beta2 subtype)

Beyond the preview

Go deeper on BR-9003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR-9003.

Explore the full profile